MADRIGAL PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Deferred Tax Assets, Operating Loss Carryforwards of $214.43 million as of 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2025-02-26
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $214.43M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $121.55M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $68.31M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards $47.86M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2024-12-31 | $214.43M 10-K · filed 2025-02-26 | |
| 2023-12-31 | $121.55M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $68.31M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $47.86M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $27.93M 10-K/A · filed 2023-03-03 | |
| 2019-12-31 | $17.64M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $14.85M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $9.23M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $12.75M 10-K · filed 2019-02-27 | $12.75M 10-K · filed 2017-03-31 |
| 2015-12-31 | $7.32M 10-K · filed 2017-03-31 | $213.00M 10-K · filed 2016-03-15 |
| 2014-12-31 | $194.09M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $170.56M 10-K · filed 2015-03-12 | |
| 2012-12-31 | $143.99M 10-K · filed 2014-03-11 | |
| 2011-12-31 | $123.46M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |